NCT04601181View on ClinicalTrials.gov

Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

October 15, 2022

Study Completion Date

October 15, 2023

Conditions
B Cell Malignancy
Interventions
BIOLOGICAL

ThisCART22 cells injection

"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"

Trial Locations (1)

230001

RECRUITING

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

UNKNOWN

lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

NCT04601181 - Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies | Biotech Hunter | Biotech Hunter